Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brendan Kane

Podiatrist, Foot & Ankle Surgery Lewes, DE Doctor of Podiatric Medicine

NPI 1699146480 CMS profile 4631464

17425 Ocean One Plz Unit 1, Lewes, DE 19958

Open in the dashboard

General payments

$11,079

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brendan Kane of Lewes, DE is reported in the CMS Open Payments database as having received $11,079 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $399 7
2024 General $2,301 18
2023 General $1,892 35
2022 General $4,807 34
2021 General $1,124 20
2020 General $219 6
2019 General $336 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brendan Kane
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Brendan Kane were reported at $399. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Brendan Kane Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $336 $389 $118–$1,406 $163
2020 $219 $191 $62–$691 $114
2021 $1,124 $329 $104–$1,341 $132
2022 $4,807 $419 $125–$1,611 $149
2023 $1,892 $377 $128–$1,164 $160
2024 $2,301 $394 $134–$1,168 $164
2025 $399 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,961 29 payments
  2. SeaPearl Inc $2,442 4 payments
  3. Medline Industries, Inc. $1,731 9 payments
  4. Supreme Orthopedic Systems, LLC $764 14 payments
  5. Arthrex, Inc. $756 12 payments
  6. Zimmer Biomet Holdings, Inc. $544 8 payments
  7. Organogenesis Inc. $416 9 payments
  8. Kerecis Limited $307 2 payments
  9. Nevro Corp. $211 6 payments
  10. DePuy Synthes Sales Inc. $156 4 payments
  11. Other $792 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,362 111 payments
  2. Education $2,400 2 payments
  3. Travel and Lodging $2,317 14 payments
Products named General payments · program years 2019–2025
  1. AUGMENT INJECTABLE $662 5 payments
  2. VARIAX $558 4 payments
  3. ALLOWRAP $387 3 payments
  4. ACTISHIELD CF $357 4 payments
  5. Kerecis Omega3 SurgiClose $307 2 payments
  6. Kerecis Omega3 GraftGuide $307 2 payments
  7. Puraply $205 4 payments
  8. 1688 $168 1 payment
  9. ACTISHIELD $161 1 payment
  10. Kerecis Omega3 Marigen $158 1 payment
  11. Other $3,923 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

239

Median for Podiatry: 160

Drug cost

$16,890

Median for Podiatry: $2,368

Branded share of claims

15.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 13 $14,481
Ketoconazole Generic 55 $1,366
Meloxicam Generic 72 $262
Terbinafine Hcl Generic 20 $222
Methylprednisolone Generic 24 $186
Colchicine Generic 13 $126
Cephalexin Generic 17 $106
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $79
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$239,520

Of which drugs: $58,102

Medicare patients

684

Average age 76

Services billed

13,547

400 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 36%
Diabetes 30%
Depression 23%
Atrial fibrillation 20%
Chronic kidney disease 19%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record